

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Spesolimab for treating generalised pustular psoriasis flares ID3963

Provisional Stakeholder List


Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Boehringer Ingelheim Ltd	All Wales Therapeutics and Toxicology
(spesolimab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Changing Faces	Wales
Gene People	British National Formulary
Genetic Alliance UK	Care Quality Commission
Psoriasis and Psoriatic Arthritis	• Department of Health - Northern Ireland
Alliance	Healthcare Improvement Scotland
Psoriasis Association	Medicines and Healthcare products
Psoriasis Help Organisation	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
Healtheare professional groups	NHS Confederation
 Healthcare professional groups Association of Genetic Nurses & 	Scottish Medicines Consortium
Counsellors	Welsh Government
 British Association of Dermatologists 	Welsh Health Specialised Services
 British Dermatological Nursing Group 	Committee
 British Geriatrics Society 	Possible comparator companies
 British Society for Cutaneous Allergy 	 AbbVie (adalimumab, risankizumab)
 British Society for Genetic Medicine 	 Abbyle (adainfulfiab, fisarkizuffab) Accord Healthcare (methotrexate)
 Primary Care Dermatology Society 	 Advanz Pharma (methotrexate)
 Royal College of General Practitioners 	 Advanz i narma (methotiexate) Almirall (dimethyl fumarate,
 Royal College of Nursing 	tildrakizumab)
 Royal College of Pathologists 	 Amgen (adalimumab, apremilast)
 Royal College of Physicians 	 Aspire Pharma (dimethyl fumarate)
 Royal Pharmaceutical Society 	 Biogen Idec (adalimumab, dimethyl
 Royal Society of Medicine 	fumarate, etanercept, infliximab)
 St John's Institute of Dermatology 	Bristol Myers Squibb (deucravacitinib)
UK Clinical Pharmacy Association	 B&S Colorama (ciclosporin)
	Celltrion Healthcare UK (adalimumab,
Others	infliximab)
Department of Health and Social Care	Celix Pharma (dimethyl fumarate)
NHS England	 Dexcel-Pharma (ciclosporin)
	 Eli Lilly and Company (ixekizumab)

Provisional stakeholder list for the evaluation of spesolimab for treating generalised pustular psoriasis flares ID3963



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Fresenius Kabi (adalimumab) Genus Pharmaceuticals (acitretin, dimethyl fumarate) Hospira UK (methotrexate) Johnson & Johnson Innovative Medicine (guselkumab, ustekinumab) Leo Pharma (brodalumab) Medac GmbH (methotrexate) Merck Sharp & Dohme (infliximab) Morningside Healthcare (acitretin, ciclosporin, methotrexate) Mylan (ciclosporin, dimethyl fumarate) Nordic Pharma (methotrexate) Novartis Pharmaceuticals UK (ciclosporin, secukinumab) Orion Pharma (UK) (methotrexate) Pfizer (etanercept, infliximab, methotrexate) Pfizer (etanercept, infliximab, methotrexate) Sandoz (adalimumab, etanercept, infliximab, methotrexate) Santen UK (ciclosporin) Teva UK (acitretin, ciclosporin, methotrexate) UCB Pharma (bimekizumab, certolizumab pegol) Viatris (ciclosporin) Wockhardt (dimethyl fumarate)
	 <u>Relevant research groups</u> British Skin Foundation Centre of Evidence-based Dermatology, University of Nottingham Cochrane Skin Group Dermatrust Genomics England MRC Clinical Trials Unit National Institute for Health Research <u>Associated Public Health groups</u> Public Health Wales

Provisional stakeholder list for the evaluation of spesolimab for treating generalised pustular psoriasis flares ID3963



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.

Provisional stakeholder list for the evaluation of spesolimab for treating generalised pustular psoriasis flares ID3963